Moderna Inc (MRNA)
Cash ratio
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Cash and cash equivalents | US$ in thousands | 2,907,000 | 3,205,000 | 6,848,000 | 2,624,000 | 236,000 |
| Short-term investments | US$ in thousands | 5,697,000 | 6,697,000 | 3,879,000 | 1,983,760 | 867,124 |
| Total current liabilities | US$ in thousands | 3,015,000 | 4,923,000 | 9,128,000 | 4,389,000 | 143,115 |
| Cash ratio | 2.85 | 2.01 | 1.18 | 1.05 | 7.71 |
December 31, 2023 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($2,907,000K
+ $5,697,000K)
÷ $3,015,000K
= 2.85
The cash ratio of Moderna Inc has shown fluctuating trends over the past five years. In 2019, the company had a notably high cash ratio of 7.77, indicating a strong ability to cover short-term liabilities solely with its cash and cash equivalents. However, this ratio decreased significantly in the following years, reaching 1.10 in 2020 and further declining to 1.24 in 2021.
The cash ratio improved in 2022 to 2.11, suggesting a better liquidity position compared to the previous year. This improvement indicates that the company may have increased its cash reserves relative to its short-term obligations, which could reflect prudent financial management practices.
In 2023, the cash ratio further improved to 3.00, signaling a more robust ability to meet short-term financial obligations using readily available cash resources. A higher cash ratio typically indicates a lower risk of liquidity issues and a stronger financial position in the short term for the company.
Overall, while the cash ratio of Moderna Inc has experienced variability in recent years, the upward trend in 2022 and 2023 suggests an enhanced liquidity position and improved capability to meet its short-term obligations with cash on hand.
Peer comparison
Dec 31, 2023